Security key
04351P101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 45,989,019
- Total 13F value
- $5,412,737,939
- Share change
- +5,906,750
- Put/Call ratio
- 39%
- SEC-reported price per share
- $117.70
- Number of holders
- 137
- Value change
- +$716,635,309
- Number of buys
- 88
- Number of sells
- 53
- Shares outstanding
- 62,915,156
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2019
Institutions
137
Top holders
10
ASND full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2019
Previous quarter: Q4 2018
Ascendis Pharma A/S SEC filings
Ascendis Pharma A/S company facts
Broader feeds
Reporting periods
Holder history for CUSIP 04351P101
Recent filing periods:
Ownership snapshot
Top reported holders of ASND - Ascendis Pharma A/S - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2018
13F
Lead comparable stake: 6.7%
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 6.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 5
RA CAPITAL MANAGEMENT, L.P.
6.7%
FMR LLC
6.7%
PRICE T ROWE ASSOCIATES INC /MD/
6.5%
ORBIMED ADVISORS LLC
6.5%
BAKER BROS. ADVISORS LP
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
6.7%
|
$265,670,000
4,240,536 shares
|
— | 31 Dec 2018 |
| FMR LLC |
13F
Company
|
6.7%
|
$263,333,000
4,203,246 shares
|
— | 31 Dec 2018 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
6.5%
|
$257,547,000
4,110,892 shares
|
— | 31 Dec 2018 |
| ORBIMED ADVISORS LLC |
13F
Company
|
6.5%
|
$256,074,000
4,087,373 shares
|
— | 31 Dec 2018 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
4.5%
|
$177,760,000
2,837,352 shares
|
— | 31 Dec 2018 |
| Vivo Capital, LLC |
13F
Company
|
3.4%
|
$135,752,000
2,166,832 shares
|
— | 31 Dec 2018 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2019
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
137
Shares
45,989,019
Rows available
137
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2019 vs Q4 2018 Across Filers
Q4 2018 holders
102
Q1 2019 holders
137
Holder diff
35
| Investor | Q4 2018 Shares | Q1 2019 Shares | Share Diff | Share Chg % | Q4 2018 value | Q1 2019 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend